Free Trial

TransMedics Group (TMDX) Stock Forecast & Price Target

TransMedics Group logo
$77.20 -5.72 (-6.90%)
(As of 11/20/2024 ET)

TransMedics Group - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
10

Based on 11 Wall Street analysts who have issued ratings for TransMedics Group in the last 12 months, the stock has a consensus rating of "Buy." Out of the 11 analysts, 1 has given a hold rating, 9 have given a buy rating, and 1 has given a strong buy rating for TMDX.

Consensus Price Target

$131.80
70.73% Upside
According to the 11 analysts' twelve-month price targets for TransMedics Group, the average price target is $131.80. The highest price target for TMDX is $178.00, while the lowest price target for TMDX is $104.00. The average price target represents a forecasted upside of 70.73% from the current price of $77.20.
Get the Latest News and Ratings for TMDX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for TransMedics Group and its competitors.

Sign Up

TMDX Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$131.80$174.30$171.44$79.83
Forecasted Upside70.73% Upside41.78% Upside-2.40% Downside15.78% Upside
Consensus Rating
Buy
Buy
Moderate Buy
Moderate Buy

TMDX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TMDX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

TransMedics Group Stock vs. The Competition

TypeTransMedics GroupMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside70.73% Upside26,931.55% Upside9.81% Upside
News Sentiment Rating
Positive News

See Recent TMDX News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/20/2024Piper Sandler
2 of 5 stars
 Lower TargetOverweight ➝ Overweight$180.00 ➝ $110.00+41.79%
11/20/2024Canaccord Genuity Group
1 of 5 stars
 Lower TargetBuy ➝ Buy$109.00 ➝ $104.00+26.06%
11/18/2024TD Cowen
4 of 5 stars
 Lower TargetBuy ➝ Buy$175.00 ➝ $120.00+48.64%
10/29/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$173.00 ➝ $116.00+30.34%
10/29/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$200.00 ➝ $150.00+18.82%
10/29/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$200.00 ➝ $125.00-0.98%
10/29/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Matson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$208.00 ➝ $109.00-13.66%
9/24/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Rescott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/2/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Sellers
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$151.00 ➝ $178.00+18.98%
7/15/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$104.00 ➝ $145.00+0.58%
6/6/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$161.00+21.03%
7/19/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Daniels
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/23/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$70.00 ➝ $75.00+16.21%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:41 AM ET.


TMDX Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for TransMedics Group is $131.80, with a high forecast of $178.00 and a low forecast of $104.00.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last twelve months. There is currently 1 hold rating, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TMDX shares.

According to analysts, TransMedics Group's stock has a predicted upside of 70.73% based on their 12-month stock forecasts.

Over the previous 90 days, TransMedics Group's stock had 1 upgrade by analysts.

TransMedics Group has been rated by research analysts at Baird R W, Canaccord Genuity Group, JPMorgan Chase & Co., Needham & Company LLC, Oppenheimer, Piper Sandler, Robert W. Baird, and TD Cowen in the past 90 days.

Analysts like TransMedics Group more than other "medical" companies. The consensus rating for TransMedics Group is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TMDX compares to other companies.


This page (NASDAQ:TMDX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners